Granules India’s Paracetamol API facility completes USFDA inspection

16 Jun 2014 Evaluate

Granules India’s Paracetamol facility has successfully passed a USFDA inspection without any 483 observations. This facility has the world’s largest single API production line by volume.

Granules’ four API facilities have successfully passed USFDA inspections in the past 12 months. All of the company’s facilities including its finished dosage and PFI facility are approved by leading regulatory agencies including the USFDA, EDQM, Health Canada and Korean FDA.

Granules India is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.

Granules India Share Price

558.90 13.45 (2.47%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.